Ravidasvir
- Generic Name
- Ravidasvir
- Drug Type
- Small Molecule
- Chemical Formula
- C42H50N8O6
- CAS Number
- 1242087-93-9
- Unique Ingredient Identifier
- AL3G001BI8
- Background
Ravidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).
- Indication
联合利托那韦强化的达诺瑞韦钠片和利巴韦林，用于治疗初治的基因1b型慢性丙型肝炎病毒感染的非肝硬化成人患者，不得作为单药治疗。
A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
Phase 2
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2016-04-07
- Lead Sponsor
- Pharco Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT02371408
- Locations
- 🇪🇬
National Liver Institute, Menoufiya, Egypt
🇪🇬Al-Qahira Al-Fatimeya MoH Hospital, Cairo, Egypt
🇪🇬Kasr El Aini Viral Hepatitis Center, Cairo, Egypt
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: BI 207127 Dose 1Drug: BI 207127 Dose 2Drug: BI 207127 Placebo
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01859962
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
Phase 1
Completed
- Conditions
- Pharmacokinetic Assessments in Healthy Volunteers
- Interventions
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01786382
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01448200
- Locations
- 🇳🇿
Investigational site, Christchurch, New Zealand
🇺🇸Investigational Site, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath